BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qiu W, Christakis I, Silva A, Bassett RL Jr, Cao L, Meng QH, Gardner Grubbs E, Zhao H, Yao JC, Lee JE, Perrier ND. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol (Oxf) 2016;85:400-7. [PMID: 27256431 DOI: 10.1111/cen.13119] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Cheng Z, Guo D, Ruzi A, Pan T, You K, Chen Y, Huang X, Zhang J, Yang F, Niu L, Xu K, Li Y. Modeling MEN1 with Patient-Origin iPSCs Reveals GLP-1R Mediated Hypersecretion of Insulin. Cells 2022;11:2387. [DOI: 10.3390/cells11152387] [Reference Citation Analysis]
2 Naber MR, Ahmad S, Verrijn Stuart AA, Giles RH, Valk GD, van Leeuwaarde RS. Is There a Role for Biomarkers in Surveillance of Pancreatic Neuroendocrine Neoplasms in Von Hippel-Lindau Disease? Journal of the Endocrine Society 2022;6:bvab191. [DOI: 10.1210/jendso/bvab191] [Reference Citation Analysis]
3 Thompson R, Landry CS. Multiple endocrine neoplasia 1: a broad overview. Ther Adv Chronic Dis 2021;12:20406223211035288. [PMID: 34413971 DOI: 10.1177/20406223211035288] [Reference Citation Analysis]
4 Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020;49:863-81. [PMID: 32675783 DOI: 10.1097/MPA.0000000000001597] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 41.0] [Reference Citation Analysis]
5 Cuthbertson DJ, Barriuso J, Lamarca A, Manoharan P, Westwood T, Jaffa M, Fenwick SW, Nuttall C, Lalloo F, Prachalias A, Pizanias M, Wieshmann H, McNamara MG, Hubner R, Srirajaskanthan R, Vivian G, Ramage J, Weickert MO, Pritchard DM, Vinjamuri S, Valle J, Yip VS. The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. Front Endocrinol (Lausanne) 2021;12:654975. [PMID: 34163434 DOI: 10.3389/fendo.2021.654975] [Reference Citation Analysis]
6 Shirali AS, Pieterman CRC, Lewis MA, Hyde SM, Makawita S, Dasari A, Thosani N, Ikoma N, McCutcheon IE, Waguespack SG, Perrier ND. It's not a mystery, it's in the history: Multidisciplinary management of multiple endocrine neoplasia type 1. CA Cancer J Clin 2021;71:369-80. [PMID: 34061974 DOI: 10.3322/caac.21673] [Reference Citation Analysis]
7 Effraimidis G, Knigge U, Rossing M, Oturai P, Rasmussen ÅK, Feldt-Rasmussen U. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Semin Cancer Biol 2021:S1044-579X(21)00112-7. [PMID: 33905872 DOI: 10.1016/j.semcancer.2021.04.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
8 Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev 2021;42:133-70. [PMID: 33249439 DOI: 10.1210/endrev/bnaa031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Vialon M, Desailloud R, Caron P. La néoplasie endocrinienne multiple de type 1 : mise au point après le congrès de l’ENETS 2019: Multiple Endocrine Neoplasia Type 1: Development after the ENETS 2019 Congress. Ann Endocrinol (Paris) 2019;80 Suppl 1:S19-28. [PMID: 31606058 DOI: 10.1016/S0003-4266(19)30113-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018;14:656-669. [PMID: 30158549 DOI: 10.1038/s41574-018-0082-5] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 17.7] [Reference Citation Analysis]
11 Kamilaris CDC, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis.Front Endocrinol (Lausanne). 2019;10:339. [PMID: 31263451 DOI: 10.3389/fendo.2019.00339] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
12 Kemm MH, Manly CD, Hoang TD, Mai VQ, Shakir MKM. Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature. Case Rep Gastrointest Med. 2019;2019:9462942. [PMID: 31183223 DOI: 10.1155/2019/9462942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Fisher AV, Lopez-Aguiar AG, Rendell VR, Pokrzywa C, Rocha FG, Kanji ZS, Poultsides GA, Makris EA, Dillhoff ME, Beal EW, Fields RC, Panni RZ, Idrees K, Smith PM, Cho CS, Beems MV, Maithel SK, Winslow ER, Abbott DE, Weber SM. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2019;23:651-8. [PMID: 30659439 DOI: 10.1007/s11605-018-04080-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
14 Pulvirenti A, Rao D, Mcintyre CA, Gonen M, Tang LH, Klimstra DS, Fleisher M, Ramanathan LV, Reidy-Lagunes D, Allen PJ. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford). 2019;21:612-618. [PMID: 30366884 DOI: 10.1016/j.hpb.2018.09.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
15 Marx SJ. Recent Topics Around Multiple Endocrine Neoplasia Type 1. J Clin Endocrinol Metab. 2018;103:1296-1301. [PMID: 29897580 DOI: 10.1210/jc.2017-02340] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
16 van Treijen MJC, van Beek DJ, van Leeuwaarde RS, Vriens MR, Valk GD. Diagnosing Nonfunctional Pancreatic NETs in MEN1: The Evidence Base. J Endocr Soc. 2018;2:1067-1088. [PMID: 30202829 DOI: 10.1210/js.2018-00087] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
17 Al-Salameh A, Baudry C, Cohen R. Update on multiple endocrine neoplasia Type 1 and 2. Presse Med 2018;47:722-31. [PMID: 29909163 DOI: 10.1016/j.lpm.2018.03.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
18 Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, Faggiano A. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocrine-Related Cancer 2018;25:R11-29. [DOI: 10.1530/erc-17-0269] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
19 Kornaczewski Jackson ER, Pointon OP, Bohmer R, Burgess JR. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1. J Clin Endocrinol Metab 2017;102:1926-33. [PMID: 28323985 DOI: 10.1210/jc.2016-3865] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
20 Manoharan J, Albers MB, Bartsch DK. The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies. Endocr Relat Cancer 2017;24:T209-25. [PMID: 28790162 DOI: 10.1530/ERC-17-0231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
21 Mendelson AH, Donowitz M. Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome.Dig Dis Sci. 2017;62:2258-2265. [PMID: 28776139 DOI: 10.1007/s10620-017-4695-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
22 van Leeuwaarde RS, de Laat JM, Pieterman CRC, Dreijerink K, Vriens MR, Valk GD. The future: medical advances in MEN1 therapeutic approaches and management strategies. Endocr Relat Cancer 2017;24:T179-93. [PMID: 28768698 DOI: 10.1530/ERC-17-0225] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 2.8] [Reference Citation Analysis]
23 Hyde SM, Cote GJ, Grubbs EG. Genetics of Multiple Endocrine Neoplasia Type 1/Multiple Endocrine Neoplasia Type 2 Syndromes. Endocrinology and Metabolism Clinics of North America 2017;46:491-502. [DOI: 10.1016/j.ecl.2017.01.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
24 Qiu W, Christakis I, Stewart AA, Vodopivec DM, Silva-figueroa A, Chen H, Woodard TL, Halperin DM, Lee JE, Yao JC, Perrier ND. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1? Clin Endocrinol 2017;86:791-7. [DOI: 10.1111/cen.13324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
25 Qin S, Chen N, Yang X, Wang Q, Wang K, Huang J, Liu J, Zhou M. Development of Dual-Aptamers for Constructing Sandwich-Type Pancreatic Polypeptide Assay. ACS Sens 2017;2:308-15. [PMID: 28723135 DOI: 10.1021/acssensors.6b00836] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]